‌

US Patent 11879004 Modified binding polypeptides for optimized drug conjugation

Patent 11879004 was granted and assigned to Genzyme on January, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Marie-Priscille Brun0

Qun Zhou0

Huawei Qiu0

Sunghae Park0

Francis Duffieux0

Date of Patent

January 23, 2024

0

Patent Application Number

171870390

Date Filed

February 26, 2021

0

Patent Citations

US Patent 8163881 Immunoglobulin molecules with improved characteristics

0

US Patent 6998253 Altered polypeptides with increased half-life

0

US Patent 7083784 Molecules with extended half-lives, compositions and uses thereof

0

US Patent 7521541 Cysteine engineered antibodies and conjugates

0

US Patent 7612181 Dual variable domain immunoglobulin and uses thereof

0

US Patent 10744204 Conjugated compounds comprising cysteine-engineered antibodies

0

Patent Primary Examiner

0

Patent abstract

Engineered antibodies that are stable and can be conjugated to a ligand or drug at a ligand/drug to antibody ratio of above 3, making these conjugates suitable for treatment of a variety of indications, are provided. Methods of producing these engineered antibodies are also provided.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11879004 Modified binding polypeptides for optimized drug conjugation

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool